273 related articles for article (PubMed ID: 34605709)
1. PD-L1
Zhou L; Wang J; Lyu SC; Pan LC; Shi XJ; Du GS; He Q
Technol Cancer Res Treat; 2021; 20():15330338211045820. PubMed ID: 34605709
[No Abstract] [Full Text] [Related]
2. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of neutrophils-to-lymphocytes ratio (NLR), PD-L1 expression, and tumor immune microenvironment in laryngeal cancer.
Franz L; Alessandrini L; Fasanaro E; Gaudioso P; Carli A; Nicolai P; Marioni G
Ann Diagn Pathol; 2021 Feb; 50():151657. PubMed ID: 33189034
[TBL] [Abstract][Full Text] [Related]
4. Expressions of Immune Negative Regulator FoxP3+Treg and PD-L1 Protein in the Immune Microenvironment of Cervical Lesion.
Ma Q; Zhao M; Wei X; Zhao J; Yang T; Zhang Q; Wang K; Yang X
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Feb; 39(1):128-132. PubMed ID: 28270295
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Role and Clinical Association of Tumor-Infiltrating Lymphocyte, Programmed Death Ligand-1 Expression with Neutrophil-Lymphocyte Ratio in Locally Advanced Triple-Negative Breast Cancer.
Lee J; Kim DM; Lee A
Cancer Res Treat; 2019 Apr; 51(2):649-663. PubMed ID: 30064200
[TBL] [Abstract][Full Text] [Related]
6. Lenvatinib Targets FGF Receptor 4 to Enhance Antitumor Immune Response of Anti-Programmed Cell Death-1 in HCC.
Yi C; Chen L; Lin Z; Liu L; Shao W; Zhang R; Lin J; Zhang J; Zhu W; Jia H; Qin L; Lu L; Chen J
Hepatology; 2021 Nov; 74(5):2544-2560. PubMed ID: 34036623
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
8. Relationship and clinical significance of TGF-beta1 expression with Treg cell infiltration in hepatocellular carcinoma.
Lin GH; Wang J; Li SH; Wang J; Xu L; Li SP
Chin J Cancer; 2010 Apr; 29(4):403-7. PubMed ID: 20346216
[TBL] [Abstract][Full Text] [Related]
9. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
[TBL] [Abstract][Full Text] [Related]
10. Peritumoural neutrophils negatively regulate adaptive immunity via the PD-L1/PD-1 signalling pathway in hepatocellular carcinoma.
He G; Zhang H; Zhou J; Wang B; Chen Y; Kong Y; Xie X; Wang X; Fei R; Wei L; Chen H; Zeng H
J Exp Clin Cancer Res; 2015 Nov; 34():141. PubMed ID: 26581194
[TBL] [Abstract][Full Text] [Related]
11. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation.
Itoh S; Yoshizumi T; Yugawa K; Imai D; Yoshiya S; Takeishi K; Toshima T; Harada N; Ikegami T; Soejima Y; Kohashi K; Oda Y; Mori M
Hepatology; 2020 Dec; 72(6):1987-1999. PubMed ID: 32112577
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 Expression Level Displays a Positive Correlation with Immune Response in Pancreatic Cancer.
Zhao L; Cao Y
Dis Markers; 2020; 2020():8843146. PubMed ID: 33062072
[TBL] [Abstract][Full Text] [Related]
13. Regulatory T cells, especially ICOS
Tu JF; Ding YH; Ying XH; Wu FZ; Zhou XM; Zhang DK; Zou H; Ji JS
Sci Rep; 2016 Oct; 6():35056. PubMed ID: 27725696
[TBL] [Abstract][Full Text] [Related]
14. Low expressions of PD-L1 and CTLA-4 by induced CD4
Zhao L; Zhou X; Zhou X; Wang H; Gu L; Ke Y; Zhang M; Ji X; Yang X
Cytokine; 2020 Sep; 133():155119. PubMed ID: 32535334
[TBL] [Abstract][Full Text] [Related]
15. Intrahepatic interleukin-17+ T cells and FoxP3+ regulatory T cells cooperate to promote development and affect the prognosis of hepatocellular carcinoma.
Huang Y; Wang F; Wang Y; Zhu Z; Gao Y; Ma Z; Xu R; Du Z
J Gastroenterol Hepatol; 2014 Apr; 29(4):851-9. PubMed ID: 24303990
[TBL] [Abstract][Full Text] [Related]
16. Clinical prognostic value of CD4+CD25+FOXP3+regulatory T cells in peripheral blood of Barcelona Clinic Liver Cancer (BCLC) stage B hepatocellular carcinoma patients.
Li F; Guo Z; Lizée G; Yu H; Wang H; Si T
Clin Chem Lab Med; 2014 Sep; 52(9):1357-65. PubMed ID: 24646790
[TBL] [Abstract][Full Text] [Related]
17. The predictive and prognostic value of Foxp3+/CD25+ regulatory T cells and PD-L1 expression in triple negative breast cancer.
Zhang L; Wang XI; Ding J; Sun Q; Zhang S
Ann Diagn Pathol; 2019 Jun; 40():143-151. PubMed ID: 31096176
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of programmed cell death ligand 1 (PD-L1) for hepatocellular carcinoma: a meta-analysis.
Li XS; Li JW; Li H; Jiang T
Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32255189
[TBL] [Abstract][Full Text] [Related]
19. The Severity of Liver Fibrosis Influences the Prognostic Value of Inflammation-Based Scores in Hepatitis B-Associated Hepatocellular Carcinoma.
Wang Q; Blank S; Fiel MI; Kadri H; Luan W; Warren L; Zhu A; Deaderick PA; Sarpel U; Labow DM; Hiotis SP
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1125-32. PubMed ID: 26159441
[TBL] [Abstract][Full Text] [Related]
20. Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung.
Tashima Y; Kuwata T; Yoneda K; Hirai A; Mori M; Kanayama M; Imanishi N; Kuroda K; Ichiki Y; Tanaka F
Sci Rep; 2020 Jan; 10(1):1243. PubMed ID: 31988315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
